Cargando…

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizvi, Naiyer, Ademuyiwa, Foluso O, Cao, Z Alexander, Chen, Helen X, Ferris, Robert L, Goldberg, Sarah B, Hellmann, Matthew D, Mehra, Ranee, Rhee, Ina, Park, Jong Chul, Kluger, Harriet, Tawbi, Hussein, Sullivan, Ryan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016262/
https://www.ncbi.nlm.nih.gov/pubmed/36918220
http://dx.doi.org/10.1136/jitc-2022-005920
_version_ 1784907369849815040
author Rizvi, Naiyer
Ademuyiwa, Foluso O
Cao, Z Alexander
Chen, Helen X
Ferris, Robert L
Goldberg, Sarah B
Hellmann, Matthew D
Mehra, Ranee
Rhee, Ina
Park, Jong Chul
Kluger, Harriet
Tawbi, Hussein
Sullivan, Ryan J
author_facet Rizvi, Naiyer
Ademuyiwa, Foluso O
Cao, Z Alexander
Chen, Helen X
Ferris, Robert L
Goldberg, Sarah B
Hellmann, Matthew D
Mehra, Ranee
Rhee, Ina
Park, Jong Chul
Kluger, Harriet
Tawbi, Hussein
Sullivan, Ryan J
author_sort Rizvi, Naiyer
collection PubMed
description Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved response rates have been demonstrated with the addition of ICIs to cytotoxic therapies, leading to approvals from the US Food and Drug Administration and regulatory agencies in other countries for ICI−chemotherapy combinations in a number of solid tumor indications, including breast, head and neck, gastric, and lung cancer. Designing trials for patients with tumors that do not respond or stop responding to treatment with immunotherapy combinations, however, is challenging without uniform definitions of resistance. Previously, the Society for Immunotherapy of Cancer (SITC) published consensus definitions for resistance to single-agent anti-programmed cell death protein 1 (PD-1). To provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance to ICI-based combinations, SITC convened a follow-up workshop in 2021 to develop consensus definitions for resistance to multiagent ICI combinations. This manuscript reports the consensus clinical definitions for combinations of ICIs and chemotherapies. Definitions for resistance to ICIs in combination with targeted therapies and with other ICIs will be published in companion volumes to this paper.
format Online
Article
Text
id pubmed-10016262
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100162622023-03-16 Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy Rizvi, Naiyer Ademuyiwa, Foluso O Cao, Z Alexander Chen, Helen X Ferris, Robert L Goldberg, Sarah B Hellmann, Matthew D Mehra, Ranee Rhee, Ina Park, Jong Chul Kluger, Harriet Tawbi, Hussein Sullivan, Ryan J J Immunother Cancer Position Article and Guidelines Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occurs after an interval of initial control. Improved response rates have been demonstrated with the addition of ICIs to cytotoxic therapies, leading to approvals from the US Food and Drug Administration and regulatory agencies in other countries for ICI−chemotherapy combinations in a number of solid tumor indications, including breast, head and neck, gastric, and lung cancer. Designing trials for patients with tumors that do not respond or stop responding to treatment with immunotherapy combinations, however, is challenging without uniform definitions of resistance. Previously, the Society for Immunotherapy of Cancer (SITC) published consensus definitions for resistance to single-agent anti-programmed cell death protein 1 (PD-1). To provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance to ICI-based combinations, SITC convened a follow-up workshop in 2021 to develop consensus definitions for resistance to multiagent ICI combinations. This manuscript reports the consensus clinical definitions for combinations of ICIs and chemotherapies. Definitions for resistance to ICIs in combination with targeted therapies and with other ICIs will be published in companion volumes to this paper. BMJ Publishing Group 2023-03-14 /pmc/articles/PMC10016262/ /pubmed/36918220 http://dx.doi.org/10.1136/jitc-2022-005920 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Position Article and Guidelines
Rizvi, Naiyer
Ademuyiwa, Foluso O
Cao, Z Alexander
Chen, Helen X
Ferris, Robert L
Goldberg, Sarah B
Hellmann, Matthew D
Mehra, Ranee
Rhee, Ina
Park, Jong Chul
Kluger, Harriet
Tawbi, Hussein
Sullivan, Ryan J
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
title Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
title_full Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
title_fullStr Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
title_full_unstemmed Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
title_short Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
title_sort society for immunotherapy of cancer (sitc) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
topic Position Article and Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016262/
https://www.ncbi.nlm.nih.gov/pubmed/36918220
http://dx.doi.org/10.1136/jitc-2022-005920
work_keys_str_mv AT rizvinaiyer societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT ademuyiwafolusoo societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT caozalexander societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT chenhelenx societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT ferrisrobertl societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT goldbergsarahb societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT hellmannmatthewd societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT mehraranee societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT rheeina societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT parkjongchul societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT klugerharriet societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT tawbihussein societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy
AT sullivanryanj societyforimmunotherapyofcancersitcconsensusdefinitionsforresistancetocombinationsofimmunecheckpointinhibitorswithchemotherapy